Skip to main content
SpringerLink
Log in

Relative Bioavailability Study of a Novel Prodrug of Tenofovir, Tenofovir Dipivoxil Fumarate, in Healthy Male Fasted Volunteers

  • Original Research Article
  • Published:
Clinical Drug Investigation Aims and scope Submit manuscript

Abstract

Background and Objective: Tenofovir dipivoxil fumarate (9-[(R)-2-[[bis (pivaloyloxymethoxy) phosphinoyl] methoxy] propyl] adenine fumarate) is a novel ester prodrug of tenofovir. It has been developed as an anti-hepatitis B virus clinical candidate. The purpose of this study was to determine the pharmacokinetic parameters of tenofovir dipivoxil fumarate (test) and the commercially available tenofovir disoproxil fumarate (Viread®, reference). In addition, the bioavailability of tenofovir dipivoxil fumarate was evaluated in healthy male fasted subjects after a single comparatively equivalent dose.

Methods: This single-dose, randomized, two-way, open-label, crossover study was conducted at Xijing Hospital, Xi’an, China. The study drug was administered under fasted conditions. Serial blood samples were obtained over 72 hours after oral administration of each treatment. Bioavailability of the drug was assessed in accordance with the State Food and Drug Administration bioequivalence criteria.

Results: Eighteen subjects were enrolled and completed the study, with all study treatments being generally well tolerated. The geometric mean ratios (90% confidence interval [CI]) for maximum plasma concentration (Cmax), area under the plasma concentration-time curve from time zero to the last quantifiable concentration (AUClast), and area under the plasma concentration-time curve from time zero extrapolated to infinity (AUC∞) were 124.49% (90% CI 115.85, 133.79), 122.85% (90% CI 115.55, 130.62), and 122.43% (90% CI 115.71, 129.54), respectively.

Conclusion: The relative bioavailability of tenofovir dipivoxil was 20% higher compared with tenofovir disoproxil fumarate; this result was consistent with the preclinical data.

Background and Objective: Tenofovir dipivoxil fumarate (9-[(R)-2-[[bis (pivaloyloxymethoxy) phosphinoyl] methoxy] propyl] adenine fumarate) is a novel ester prodrug of tenofovir. It has been developed as an anti-hepatitis B virus clinical candidate. The purpose of this study was to determine the pharmacokinetic parameters of tenofovir dipivoxil fumarate (test) and the commercially available tenofovir disoproxil fumarate (Viread®, reference). In addition, the bioavailability of tenofovir dipivoxil fumarate was evaluated in healthy male fasted subjects after a single comparatively equivalent dose.

Methods: This single-dose, randomized, two-way, open-label, crossover study was conducted at Xijing Hospital, Xi’an, China. The study drug was administered under fasted conditions. Serial blood samples were obtained over 72 hours after oral administration of each treatment. Bioavailability of the drug was assessed in accordance with the State Food and Drug Administration bioequivalence criteria.

Results: Eighteen subjects were enrolled and completed the study, with all study treatments being generally well tolerated. The geometric mean ratios (90% confidence interval [CI]) for maximum plasma concentration (Cmax), area under the plasma concentration-time curve from time zero to the last quantifiable concentration (AUClast), and area under the plasma concentration-time curve from time zero extrapolated to infinity (AUC∞) were 124.49% (90% CI 115.85, 133.79), 122.85% (90% CI 115.55, 130.62), and 122.43% (90% CI 115.71, 129.54), respectively.

Conclusion: The relative bioavailability of tenofovir dipivoxil was 20% higher compared with tenofovir disoproxil fumarate; this result was consistent with the preclinical data.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Table I

Similar content being viewed by others

References

  1. Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J viral hepatitis 2004; 11: 97–107

    Article  CAS  Google Scholar 

  2. Srinivas RV, Fridland A. Antiviral activities of 9-R-2-phosphonomethoxypropyl adenine (PMPA) against various drug-resistant human immunodeficiency virus strains. Antimicrob Agents Chemother 1998; 42: 1484–7

    PubMed  CAS  Google Scholar 

  3. Wainberg MA, Miller MD, Quan YD, et al. In vitro selection and characterization of HIV-1 with reduced susceptibility to PMPA. Antivir Ther 1999; 4: 87–94

    PubMed  CAS  Google Scholar 

  4. Arimilli M, Kim C, Bischofberger N, et al. Synthesis, in vitro biological evaluation and oral bioavailability of prodrugs of the antiretroviral agent 9-[2-(phosphonomethoxy)-propyl]adenine (PMA). Antiviral Chem Chemother 1997; 8: 557–64

    CAS  Google Scholar 

  5. Shaw JP, Sueoka CM, Oliyai R, et al. Metabolism and pharmacokinetics of novel oral prodrugs of 9-[(R)-2-(phos-phonomethoxy)-propyl]adenine (PMPA) in dogs. Pharm Res 1997; 14: 1824–9

    Article  PubMed  CAS  Google Scholar 

  6. Robbins BL, Srinivas RV, Kim C, et al. Anti-human immunodeficiency virus activity and cellular metabolism of a potential prodrug of the acyclic nucleoside phosphonate 9-R-(2-phosphonomethoxypropyl) adenine (PMPA), bis (isopropyloxymethylcarbonyl) PMPA. Antimicrob Agents Chemother 1998; 42: 612–7

    PubMed  CAS  Google Scholar 

  7. Duarte-Rojo A, Heathcote EJ. Efficacy and safety of teno-fovir disoproxil fumarate in patients with chronic hepatitis B. Ther Adv Gastroenterol 2010; 3: 107–19

    Article  CAS  Google Scholar 

  8. Marcellin P, Heathcote EJ, Buti M, et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med 2008; 359: 2442–55

    Article  PubMed  CAS  Google Scholar 

  9. Wang ZH, Huang YH, Wen SJ, et al. Hepatitis B virus genotypes and subgenotypes in China. Hepatology Res 2007; 37: 36–41

    Article  CAS  Google Scholar 

  10. Gu Y. Ph.D dissertation. Chinese Academy of Medical Science & Peking Union Medical Collegy 2011; 50-92

  11. Gallant JE, Deresinski S. Tenofovir disoproxil fumarate. Clin Infect Dis 2003; 37: 944–50

    Article  PubMed  CAS  Google Scholar 

  12. Delahunty T, Bushman L, Fletcher CV. Sensitive assay for determining plasma tenofovir concentrations by LC/MS/ MS. J Chromatogr B 2006; 830: 6–12

    Article  CAS  Google Scholar 

  13. Chinese Pharmacopeia. 2010; Part II: XIX B: Guiding principles of bioavailability and bioequivalence studies for pharmaceutical preparations in human: 195-9

  14. Barditch-Crovo P, Deeks SG, Collier A, et al. Phase I/II trial of the pharmacokinetics, safety, and antiretroviral activity of tenofovir disoproxil fumarate in human immunodeficiency virus-infected adults. Antimicrob Agents Chemother 2001; 45: 2733–9

    Article  PubMed  CAS  Google Scholar 

  15. Deeks SG, Barditch CP, Lietman PS, et al. The safety, pharmacokinetics, and antiretroviral activity of intravenous 9-[2-(R)-(phosphonomethoxy)propyl]adenine, a novel anti-human immunodeficiency virus (HIV) therapy, in HIV-infected adults. Antimicrob Agents Chemother 1998; 42: 2380–4

    PubMed  CAS  Google Scholar 

  16. Mathias AA, Hinkle J, Menning M, et al. Bioequivalence of efavirenz/emtricitabine/tenofovir disoproxil fumarate single-tablet regimen. Clin Sci 2007; 46: 167–73

    CAS  Google Scholar 

  17. US Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER). Guidance for industry. Bioavailability and bioequivalence studies for orally administered drug products-general considerations. Revision 1. Rockville (MD); 2003 [online]. Available from URL: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM070124.pdf [Accessed 2011 Oct 1]

  18. Liu MS, Guo JF, Yi H, et al. An LC-ESI-MS-MS for quantification of tenofovir octadecyloxyethyl ester in rat plasma and its application to a pharmacokinetic study. Chromatographia 2011; 74: 51–7

    Article  CAS  Google Scholar 

  19. Rompay V, Koen KA, Kearney BP, et al. Evaluation of oral tenofovir disoproxil fumarate and topical tenofovir GS-7340 to protect infant macaques against repeated oral challenges with virulent simian immunodeficiency virus. J Acquir Immune Defic Syndr 2006; 43: 6–14

    Article  PubMed  Google Scholar 

  20. Birkus G, Kutty N, He GX, et al. Activation of 9-[(R)-2-[[(S)-[[(S)-1-(Isopropoxycarbonyl) ethyl] amino] phenoxy-phosphinyl] -methoxy]propyl] adenine (GS-7340) and other tenofovir phosphonoamidate prodrugs by human proteases. Mol Pharmacol 2008; 74: 92–100

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

This study was sponsored by Chia-tai Tianqing Pharmaceutical Co., Ltd, Lianyungang, Jiangsu, China, and was carried out by Xijing hospital, Fourth Military Medical University, Xi’an, China. These authors are employees of Xijing hospital. The study participants and nurses are kindly acknowledged for their invaluable help with this study. The authors report no conflicts of interest. The authors alone are responsible for the content and writing of the paper. All authors provided a significant contribution to and read and approved the manuscript.

Author information

Authors and Affiliations

  1. Department of Pharmacy, Xijing Hospital, Fourth Military Medical University, P.O. Box 710032, Xi’an, China

    Chengtao Lu, Yanyan Jia, Jing Yang, Ying Song, Wenxing Liu, Yi Ding,  Xiaoli Sun &  Aidong Wen

Authors
  1. Chengtao Lu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yanyan Jia
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jing Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ying Song
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Wenxing Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Yi Ding
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Xiaoli Sun
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Aidong Wen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Xiaoli Sun or Aidong Wen.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lu, C., Jia, Y., Yang, J. et al. Relative Bioavailability Study of a Novel Prodrug of Tenofovir, Tenofovir Dipivoxil Fumarate, in Healthy Male Fasted Volunteers. Clin Drug Investig 32, 333–338 (2012). https://doi.org/10.2165/11599910-000000000-00000

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/11599910-000000000-00000

Keywords

Search

Navigation